On February 22, the "scientific and practical evidence of the efficiency and safety" of the Sino-Uzbek vaccine was presented to the parliament, the First Deputy Minister of Innovation Shahlo Turdikulova said in a comment to the Uzbekistan 24 TV channel.

Earlier, the third phase of clinical trials of the vaccine, developed by the Chinese company Zhifei Longcom Biopharmaceutical, started in Uzbekistan in December, as of February 22, 6835 volunteers received the first dose, 3843 people received the second and 178 volunteers received the third dose of ZF 2001 vaccine. The company recognized Uzbekistan as a co-author in the development of the jab. The vaccine will be produced jointly with Uzbek pharmacists under the name ZF-UZ-VAC 2001. Jurabek Laboratories has been selected as the partner.

“Together with our Chinese colleagues, we have created one of the most efficient and safest vaccines in the world, which received the brand name ZF-UZ-VAC 2001. This is a great achievement of our science, which has propelled our country into a small number of countries that have developed its own vaccine. This vaccine has undergone very serious clinical research. All work was carried out within very strict standards, in line with international requirements. Now this vaccine is undergoing the stage of re-registration by the WHO,” said Shakhlo Turdikulova.

“We have recently launched a call center, which deals with constant monitoring the health of vaccinated people. People will be able to contact this call center during mass vaccination. According to the results of the first and second phases of vaccination, carried out at the initial stage in China, as well as on studies of 7000 people, which we ourselves carried out here in Uzbekistan, data were obtained that the safety of the vaccine is more than 99%,” said the first deputy head of the Ministry of Innovations.

At the same time, Shahlo Turdikulova noted, there are virtually no cases of side effects from this vaccine. “If we talk about the efficiency of the vaccine, its immunogenicity was 97%, and the level of antibody production after the second dose increased by 11 times,” she said.

“Recent studies have shown a very high efficiency of the vaccine against the British and South African strains. So, compared to the Moderna vaccine [developed in the USA], it is by 6 times higher. Also, one of the important advantages is that this vaccine can be stored and transported in an ordinary refrigerator - up to 8 degrees,” she noted.

Shakhlo Turdikulova said that at the parliamentary hearings, the developers recommended the Chinese-Uzbek vaccine for widespread use based on the results of registration procedures.

At the parliamentary hearing on February 22, held at the initiative of the People's Democratic Party, the priority order of mass vaccination was also discussed.